The Hematologic Malignancy Program at Stony Brook Cancer Center treats patients with blood cancers, cancers of the lymphatic system and bone marrow disorders. Novel therapies, including treatment on clinical trials, immunotherapy, radiation therapy and chemotherapy, are designed to improve the outcome of patients with these malignancies.
The Cancer Center has thirteen multidisciplinary disease management teams. This allows patients to receive expert care close to home, where they can heal in their own community with family and friends by their side.
The Program treats patients at all disease stages of disease. The types of diseases we treat include the following:
- Acute Lymphocytic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
- Amyloidosis
- Aplastic Anemia
- Chronic Lymphocytic Leukemia (CLL)
- Chronic Myelogenous Leukemia (CML)
- Hodgkin’s Disease
- Multiple Myeloma
- Myelodysplastic Syndrome
- Myeloproliferative Disorders
- Non-Hodgkins Lymhoma
The Hematologic Malignancy Program guides the patient through all stages of treatment. At the patient’s first appointment, he or she will meet with his or her physician, nurse practitioner, and nurse coordinator who helps to educate and coordinate the patient's care. The Team works in tandem with the Stem Cell Transplant Team, to ensure a seamless transition of care from treatment to transplant. Each patient’s treatment plan, including psychosocial issues, are discussed at weekly team meetings, which provides an effortless transition between in-patient and out-patient treatment and care.